This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2005;294:2564.

	Since this article does not have an abstract, we have provided the first 136 words of the full text and any section headings.

The National Institutes of Health anticipates spending more than $150 million over the next 5 years to renew its Pharmacogenetics Research Network, a nationwide collaboration of scientists working to help physicians tailor drug prescriptions to an individual’s genetic makeup.

Since 2000, the network has provided $140 million to scientists studying genes and medications relevant to a wide range of diseases, including asthma, depression, cancer, and heart disease (http://www.nigms.nih.gov/Initiatives/PGRN/Background/FiveYear.htm).

A federally funded network of researchers is working to help physicians tailor their drug prescribing to each patient’s genetic makeup.

The new network consists of 12 groups that are examining the genetic basis for individual variation in response to medications for treating tobacco dependence, how genetic differences explain responses to tamoxifen and hormone treatments prescribed to treat breast cancer, and other drug-gene interactions.